Stay updated with breaking news from Global Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for... | April 27, 2023
Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life ... | June 18, 2023
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023
Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-1/CTLA-4... | March 27, 2023
27.03.2023 - Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from a cohort of 24 evaluable patients in an expansion of the Company’s Phase 1b study of ... Seite 1